Ezabenlimab
As of the edition of 20 October 2026, Ezabenlimab is an antibody: in active development; acts on PDCD1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2027
- Kind
- Antibody
- Registered trials
- 30, 7 stopped early
- Disease areas
- Cancer; Lungs and airways; Digestive system; Hormones; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PDCD1 | Programmed cell death protein 1 | Q15116 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 25 | 11 | 9 | 4 |
| Phase 2 | 4 | 2 | 0 | 2 |
| Phase 3 | 1 | 0 | 0 | 1 |
| All trials | 30 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Boehringer Ingelheim | Lead sponsor of trials | 2016 to now |
| OSE Immunotherapeutics | Lead sponsor of trials | 2019 to now |
| Amal Therapeutics | Lead sponsor of trials | 2019 to now |